Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 in Advanced Non-small Cell Lung Cancer
NCT03838848Phase 2Terminated
- Sponsor
- Alphamab Oncology
- Start
- May 2019
- Primary completion
- Jul 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in non-small cell lung cancer (NSCLC), sponsored by Alphamab Oncology. Started May 2019; status: terminated.
02
Drugs
erfonrilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03838848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838848.